We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-4.25%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.15B
AUM Growth
-$146M
Cap. Flow
-$28.6M
Cap. Flow %
-2.49%
Top 10 Hldgs %
82.79%
Holding
35
New
–
Increased
1
Reduced
10
Closed
2

Top Buys

Rank Stock Value
1
EHTH icon
eHealth
EHTH
+$24.7K

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.7M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.23M
3
UTHR icon
United Therapeutics
UTHR
+$3.71M
4
ALKS icon
Alkermes
ALKS
+$2.02M
5
STAA icon
STAAR Surgical
STAA
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 98.64%
2 Financials 1.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$13.3B
$171M 14.89%
2,061,373
-78,241
-4% -$6.23M
UTHR icon
2
United Therapeutics
UTHR
$22.7B
$150M 13.04%
634,806
-18,273
-3% -$3.71M
ABMD
3
DELISTED
Abiomed Inc
ABMD
$122M 10.67%
494,397
– –
INSM icon
4
Insmed
INSM
$29.4B
$115M 10.04%
5,840,398
-40,901
-0.7% -$857K
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$106M 9.22%
9,847,774
-55,987
-0.6% -$461K
STAA icon
6
STAAR Surgical
STAA
$1.25B
$78.5M 6.84%
1,106,567
-30,401
-3% -$1.96M
BIIB icon
7
Biogen
BIIB
$30.6B
$73.6M 6.42%
360,981
– –
RVNC
8
DELISTED
Revance Therapeutics, Inc.
RVNC
$60.9M 5.31%
4,405,039
-10,650
-0.2% -$164K
PRTA icon
9
Prothena Corp
PRTA
$468M
$45.7M 3.98%
1,681,477
– –
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$27.5M 2.4%
851,409
-310
-0% -$10.4K
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$304M
$27.2M 2.37%
2,491,200
– –
KPTI icon
12
Karyopharm Therapeutics
KPTI
$44.4M
$25.4M 2.21%
374,769
– –
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$5.06B
$23.6M 2.06%
1,678,196
-573,638
-25% -$10.7M
ALKS icon
14
Alkermes
ALKS
$8.29B
$18M 1.57%
603,400
-70,171
-10% -$2.02M
EHTH icon
15
eHealth
EHTH
$40.4M
$15.4M 1.35%
1,654,693
+2,433
+0.1% +$24.7K
GOSS icon
16
Gossamer Bio
GOSS
$86.1M
$14.7M 1.28%
1,750,651
-6,106
-0.3% -$47.3K
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.82B
$11.8M 1.03%
612,600
– –
ALGN icon
18
Align Technology
ALGN
$12.5B
$10.5M 0.91%
44,305
– –
EPZM
19
DELISTED
Epizyme, Inc
EPZM
$9.96M 0.87%
6,774,541
– –
ANAB icon
20
AnaptysBio
ANAB
$1.64B
$8.75M 0.76%
431,024
– –
CLVS
21
DELISTED
Clovis Oncology, Inc.
CLVS
$8.05M 0.7%
4,473,967
– –
GRTS
22
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$5.64M 0.49%
2,330,504
– –
KZR
23
DELISTED
Kezar Life Sciences
KZR
$5.43M 0.47%
65,620
– –
CYTK icon
24
Cytokinetics
CYTK
$10.8B
$4.39M 0.38%
111,717
– –
TVTX icon
25
Travere Therapeutics
TVTX
$5.74B
$4.02M 0.35%
166,069
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return

Palo Alto Investors's Q2 2022 Portfolio in Review

As of Q2 2022, Palo Alto Investors held 35 positions worth $1.15B, down 11% from $1.29B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Palo Alto Investors's Q2 2022 filing shows 1 increased, 10 reduced and 2 closed positions. The largest sale was Acadia Pharmaceuticals, an estimated $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Palo Alto Investors added most to eHealth in Q2 2022, an estimated $24.7K increase.
  • Palo Alto Investors's biggest Q2 2022 reduction was Acadia Pharmaceuticals, cutting an estimated $10.7M.
  • Palo Alto Investors fully exited Rigel Pharmaceuticals in Q2 2022, selling an estimated $1.95M.
  • Palo Alto Investors's ten largest holdings make up 83% of its $1.15B portfolio in Q2 2022.
  • Palo Alto Investors opened 0 new positions and closed 2 in Q2 2022.
  • Palo Alto Investors's portfolio value fell 11% quarter-over-quarter to $1.15B.

Based on Palo Alto Investors's 13F filing for Q2 2022, filed 15 Aug 2022.